Ongoing
Lessons from a decade of adult vaccine rollout in low- and middle-income countries: A scoping review
This paper synthesizes the insights and lessons learned from different vaccine introductions among adult populations in LMICs from the last decade (i.e., 2013 to 2023).
TbVacMod; Estimating the epidemiologic impact of new TB vaccines in high-burden settings
This is an NIH-funded study which will estimate the health impact of introducing a prevention of disease vaccine for adult and adolescents in moderate to high TB burden countries. We are developing model scenarios based on input from country stakeholders, including national TB program and immunization program officials.
Estimating the epidemiologic impact of new TB vaccines in the U.S.
This is a study funded by the American Lung Association which will explore the potential impact of targeted implementation of a prevention of disease vaccine in a low TB burden country, the U.S.A.
Acceptability and effect on public and cost-effectiveness impact
Understanding the acceptability of new TB vaccines, and their impact on health, cost-effectiveness, and budget, by socio-economic and risk group, in likely early adopter and other archetype countries.
ACEITar: Evaluation of the acceptability of new and repurposed tuberculosis vaccines in MozambiqueÂ
This is a mixed-methods study collecting information on willingness to receive a new TB vaccine among adolescents, their caretakers, and adults in Mozambique, a high TB burden country, to assess potential barriers to high uptake of new TB vaccines.
Country and target population prioritization
Evidence-based matrixing approach to identify priority countries and target populations through an iterative process, engaging a set of diverse stakeholders